Paul Matteis
Stock Analyst at Stifel
(1.22)
# 3,349
Out of 4,754 analysts
106
Total ratings
33.33%
Success rate
-12.44%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $3.73 | +195.30% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $484.98 | +1.86% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $10.80 | +196.30% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $7.22 | -16.84% | 5 | Dec 16, 2024 | |
| ALEC Alector | Downgrades: Hold | $4 | $1.44 | +178.75% | 4 | Dec 16, 2024 | |
| ANRO Alto Neuroscience | Maintains: Buy | $32 → $10 | $3.21 | +212.01% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Buy | $44 → $60 | $16.10 | +272.67% | 2 | Nov 12, 2024 | |
| ALKS Alkermes | Upgrades: Buy | $25 → $36 | $34.82 | +3.40% | 8 | Nov 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $115 → $87 | $70.39 | +23.60% | 8 | Sep 17, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $41 → $66 | $11.66 | +466.04% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $9.20 | +280.43% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $33.00 | +60.61% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 → $295 | $241.46 | +22.18% | 13 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $18.02 | +16.54% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $6.45 | +349.96% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $112.51 | +27.99% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $143.36 | +100.20% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.50 | +701.60% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.57 | +367.84% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $1.47 | +1,674.74% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $2.14 | +1,021.50% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.36 | +1,285.04% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $11.01 | +190.78% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.17 | +1,008.55% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.16 | +2,227.59% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.79 | +165.71% | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $7.72 | +81.35% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $10.98 | +482.88% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $22.48 | +1,412.46% | 1 | Dec 21, 2016 |
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $3.73
Upside: +195.30%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $484.98
Upside: +1.86%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $10.80
Upside: +196.30%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $7.22
Upside: -16.84%
Alector
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.44
Upside: +178.75%
Alto Neuroscience
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.21
Upside: +212.01%
Neurogene
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $16.10
Upside: +272.67%
Alkermes
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $34.82
Upside: +3.40%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $70.39
Upside: +23.60%
Dyne Therapeutics
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $11.66
Upside: +466.04%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $9.20
Upside: +280.43%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $33.00
Upside: +60.61%
Jun 27, 2024
Maintains: Buy
Price Target: $215 → $295
Current: $241.46
Upside: +22.18%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $18.02
Upside: +16.54%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $6.45
Upside: +349.96%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $112.51
Upside: +27.99%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $143.36
Upside: +100.20%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $2.50
Upside: +701.60%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.57
Upside: +367.84%
Oct 10, 2023
Initiates: Buy
Price Target: $26
Current: $1.47
Upside: +1,674.74%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $2.14
Upside: +1,021.50%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.36
Upside: +1,285.04%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.01
Upside: +190.78%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $2.17
Upside: +1,008.55%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.16
Upside: +2,227.59%
Jul 20, 2021
Initiates: Buy
Price Target: $26
Current: $9.79
Upside: +165.71%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $7.72
Upside: +81.35%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $10.98
Upside: +482.88%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $22.48
Upside: +1,412.46%